search
Back to results

Study to Prevent Acute Kidney Injury After Cardiac Surgery Involving Cardiopulmonary Bypass

Primary Purpose

Acute Kidney Injury

Status
Unknown status
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
ANG-3777
Placebo
Sponsored by
Angion Biomedica Corp
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Acute Kidney Injury focused on measuring CPB, Cardiac Surgery, Acute Kidney Injury

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patient is either male or female ≥ 18 years.
  2. Patient has provided written informed consent, and is willing and able to comply with the requirements of the study protocol, including screening procedures.
  3. Patient must be scheduled for and undergo a non-emergent cardiac surgical procedure involving CPB. Eligible procedures include:

    1. Coronary artery bypass graft (CABG) alone
    2. Aortic valve replacement or repair alone, with or without aortic root repair
    3. Mitral, tricuspid, or pulmonic valve replacement or repair alone
    4. Combined replacement of several cardiac valves
    5. CABG with aortic, mitral, tricuspid, or pulmonic valve replacement or repair
    6. CABG with combined cardiac valve replacement or repair.
  4. Patient must have the following risk factor(s) for AKI prior to surgery:

    1. Estimated glomerular filtration rate (eGFR) of ≥ 20 and < 30 ml/min/1.73m2, or
    2. eGFR ≥ 30 and < 60 mL/min/1.73m2 and ONE of the following Additional Risk Factors (other than age ≥ 75 years), or
    3. eGFR ≥ 60 ml/min/1.73m2 and TWO of the following Additional Risk Factors

    eGFR will be calculated using the abbreviated MDRD equation (MDRD-4, often referred to as the Levey equation): eGFR = 186.3 x sCr-1.154 x Age-0.203 x [0.742 if Female] x [1.212 if Black]

    Additional Risk Factors:

    • Combined valve and coronary surgery
    • Previous cardiac surgery with sternotomy
    • Left ventricular ejection fraction (LVEF) < 35% by invasive or noninvasive diagnostic cardiac imaging within 90 days prior to surgery
    • Diabetes mellitus requiring insulin treatment
    • Non-insulin-requiring diabetes with documented presence of at least moderate (+2 or > 100 mg/dL) proteinuria on urine analysis (medical history or dipstick)
    • Documented NYHA Class III or IV within 1 year prior to index surgery
    • Age ≥ 75 years can be considered an Additional Risk Factor only for patients with eGFR ≥ 60 ml/min/1.73m2.
  5. Patient must have presented for surgery without prior evidence of active renal injury defined as no acute rise in sCr > 0.3 mg/dL or no 50% increase in sCr between the time of Screening and pre-surgery.
  6. Patient's body mass index (BMI) < 40 at Screening.

Exclusion Criteria:

  1. Patient has eGFR < 20 mL/min/1.73 m2 within 48 hours pre-surgery as measured by MDRD 4.
  2. Patient has ongoing sepsis or partially treated infection. Sepsis is defined as the presence of a confirmed pathogen, along with fever or hypoperfusion (i.e., acidosis and new onset elevation of liver function tests) or hypotension requiring pressor use prior to surgery.
  3. Currently active infection requiring antibiotic treatment.
  4. Patient who has an active (requiring treatment) malignancy or history within 5 years prior to enrollment in the study, of solid, metastatic or hematologic malignancy with the exception of basal or squamous cell carcinoma of the skin that has been removed.
  5. Administration of iodinated contrast material within 24 hours prior to cardiac surgery.
  6. Patients diagnosed with AKI as defined by KDIGO criteria within 48 hours prior to surgery.

Sites / Locations

  • University of Southern California
  • Cedars-Sinai Medical Center
  • Stanford University Medical Center
  • California Institute of Renal Reseach
  • Yale University School of Medicine
  • Fleming Island Center for Clinical Research
  • UF Health at Unviersity of Florida
  • River City Clinical Research
  • Indiana Ohio Heart
  • University of Maryland Medical Center
  • Suburban Hospital
  • MidMichigan Medical Center Midland
  • Cardiac & Vascular Research Center of Northern Michigan
  • Bryan Heart
  • Columbia University Medical Center
  • Duke University
  • Wake Forest University School of Medicine
  • TriHealth
  • Cleveland Clinic Fairview
  • Ohio State Wexner Medical Center
  • Baylor Jack and Jane Hamilton Heart and Vascular center- Soltero Cardiovascular Research Center
  • University of Texas Southwestern Medical Center
  • University of Virginia Health System
  • Faculdade de Medicina da UNESP Campus de Botucatu
  • Instituto de Cardiologia do Rio Grande do Sul / Fundação Universitária de Cardiologia (IC - FUC)
  • Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (HCFMRP)
  • Fundação Faculdade Regional de Medicina de São José do Rio Preto
  • Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (InCor - HCFMUSP)
  • St. John Regional Hospital
  • London Health Sciences Center
  • Saint Michael's Hospital
  • CHUM - Hôtel Dieu
  • MUHC - Royal Victoria Hospital
  • Institut Universitaire de Cardiologie et de Pneumologie de Québec
  • Israeli-Georgian Medical Research Clinic Helsicore
  • New Hospitals LTD
  • Bokhua Memorial Cardiovascular Center
  • Jerarsi JSC
  • Tbilisi Heart Center
  • Acad. G. Chapidze Emergency Cardiology Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

ANG-3777

Normal Saline

Arm Description

Study drug will be administered for a total of 4 daily intravenous (IV) infusions. The first post-operative dose MUST be started within 4 hours of completing CPB. The second dose will be administered 24 ± 2 hours after completing CPB, and the third and fourth doses will be administered 24 ± 2 hours after each previous dose. Duration of administration is 30 minutes.

The placebo will be administered for a total of 4 daily intravenous (IV) infusions. The first post-operative dose MUST be started within 4 hours of completing CPB. The second dose will be administered 24 ± 2 hours after completing CPB, and the third and fourth doses will be administered 24 ± 2 hours after each previous dose. Duration of administration is 30 minutes.

Outcomes

Primary Outcome Measures

The mean AUC of the percent increase in serum creatinine above baseline

Secondary Outcome Measures

Full Information

First Posted
April 18, 2016
Last Updated
July 9, 2021
Sponsor
Angion Biomedica Corp
Collaborators
Everest Clinical Research, CTI Clinical Trial and Consulting Services, Clinical Accelerator
search

1. Study Identification

Unique Protocol Identification Number
NCT02771509
Brief Title
Study to Prevent Acute Kidney Injury After Cardiac Surgery Involving Cardiopulmonary Bypass
Official Title
A Multicenter, Prospective, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study of ANG-3777 to Assess the Safety and Efficacy of BB3 in Patients Developing Acute Kidney Injury After Cardiac Surgery
Study Type
Interventional

2. Study Status

Record Verification Date
July 2021
Overall Recruitment Status
Unknown status
Study Start Date
February 24, 2017 (Actual)
Primary Completion Date
August 2021 (Anticipated)
Study Completion Date
August 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Angion Biomedica Corp
Collaborators
Everest Clinical Research, CTI Clinical Trial and Consulting Services, Clinical Accelerator

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The objective of the study is to assess the safety and efficacy of ANG-3777 in preventing AKI compared to placebo when administered to patients at risk for developing acute kidney injury (AKI) following cardiac surgical procedures involving cardiopulmonary bypass (CPB).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Kidney Injury
Keywords
CPB, Cardiac Surgery, Acute Kidney Injury

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
275 (Actual)

8. Arms, Groups, and Interventions

Arm Title
ANG-3777
Arm Type
Active Comparator
Arm Description
Study drug will be administered for a total of 4 daily intravenous (IV) infusions. The first post-operative dose MUST be started within 4 hours of completing CPB. The second dose will be administered 24 ± 2 hours after completing CPB, and the third and fourth doses will be administered 24 ± 2 hours after each previous dose. Duration of administration is 30 minutes.
Arm Title
Normal Saline
Arm Type
Placebo Comparator
Arm Description
The placebo will be administered for a total of 4 daily intravenous (IV) infusions. The first post-operative dose MUST be started within 4 hours of completing CPB. The second dose will be administered 24 ± 2 hours after completing CPB, and the third and fourth doses will be administered 24 ± 2 hours after each previous dose. Duration of administration is 30 minutes.
Intervention Type
Drug
Intervention Name(s)
ANG-3777
Other Intervention Name(s)
Hepatocyte growth factor mimetic
Intervention Description
6 mg/mL BB3, IV, 4 days in a row, first dose must be within 4 hours after surgery, the next three doses will be approx. 24 hours after the last dose
Intervention Type
Drug
Intervention Name(s)
Placebo
Other Intervention Name(s)
Normal Saline
Intervention Description
Normal saline
Primary Outcome Measure Information:
Title
The mean AUC of the percent increase in serum creatinine above baseline
Time Frame
starting from 24 hr after the end of CPB through Day 6

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient is either male or female ≥ 18 years. Patient has provided written informed consent, and is willing and able to comply with the requirements of the study protocol, including screening procedures. Patient must be scheduled for and undergo a non-emergent cardiac surgical procedure involving CPB. Eligible procedures include: Coronary artery bypass graft (CABG) alone Aortic valve replacement or repair alone, with or without aortic root repair Mitral, tricuspid, or pulmonic valve replacement or repair alone Combined replacement of several cardiac valves CABG with aortic, mitral, tricuspid, or pulmonic valve replacement or repair CABG with combined cardiac valve replacement or repair. Patient must have the following risk factor(s) for AKI prior to surgery: Estimated glomerular filtration rate (eGFR) of ≥ 20 and < 30 ml/min/1.73m2, or eGFR ≥ 30 and < 60 mL/min/1.73m2 and ONE of the following Additional Risk Factors (other than age ≥ 75 years), or eGFR ≥ 60 ml/min/1.73m2 and TWO of the following Additional Risk Factors eGFR will be calculated using the abbreviated MDRD equation (MDRD-4, often referred to as the Levey equation): eGFR = 186.3 x sCr-1.154 x Age-0.203 x [0.742 if Female] x [1.212 if Black] Additional Risk Factors: Combined valve and coronary surgery Previous cardiac surgery with sternotomy Left ventricular ejection fraction (LVEF) < 35% by invasive or noninvasive diagnostic cardiac imaging within 90 days prior to surgery Diabetes mellitus requiring insulin treatment Non-insulin-requiring diabetes with documented presence of at least moderate (+2 or > 100 mg/dL) proteinuria on urine analysis (medical history or dipstick) Documented NYHA Class III or IV within 1 year prior to index surgery Age ≥ 75 years can be considered an Additional Risk Factor only for patients with eGFR ≥ 60 ml/min/1.73m2. Patient must have presented for surgery without prior evidence of active renal injury defined as no acute rise in sCr > 0.3 mg/dL or no 50% increase in sCr between the time of Screening and pre-surgery. Patient's body mass index (BMI) < 40 at Screening. Exclusion Criteria: Patient has eGFR < 20 mL/min/1.73 m2 within 48 hours pre-surgery as measured by MDRD 4. Patient has ongoing sepsis or partially treated infection. Sepsis is defined as the presence of a confirmed pathogen, along with fever or hypoperfusion (i.e., acidosis and new onset elevation of liver function tests) or hypotension requiring pressor use prior to surgery. Currently active infection requiring antibiotic treatment. Patient who has an active (requiring treatment) malignancy or history within 5 years prior to enrollment in the study, of solid, metastatic or hematologic malignancy with the exception of basal or squamous cell carcinoma of the skin that has been removed. Administration of iodinated contrast material within 24 hours prior to cardiac surgery. Patients diagnosed with AKI as defined by KDIGO criteria within 48 hours prior to surgery.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
John Neylan, MD
Organizational Affiliation
Angion Biomedica
Official's Role
Study Director
Facility Information:
Facility Name
University of Southern California
City
Los Angeles
State/Province
California
ZIP/Postal Code
90033
Country
United States
Facility Name
Cedars-Sinai Medical Center
City
Los Angeles
State/Province
California
ZIP/Postal Code
90048
Country
United States
Facility Name
Stanford University Medical Center
City
Palo Alto
State/Province
California
ZIP/Postal Code
94304
Country
United States
Facility Name
California Institute of Renal Reseach
City
San Diego
State/Province
California
ZIP/Postal Code
92123
Country
United States
Facility Name
Yale University School of Medicine
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06520
Country
United States
Facility Name
Fleming Island Center for Clinical Research
City
Fleming Island
State/Province
Florida
ZIP/Postal Code
32207
Country
United States
Facility Name
UF Health at Unviersity of Florida
City
Gainesville
State/Province
Florida
ZIP/Postal Code
32610
Country
United States
Facility Name
River City Clinical Research
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32207
Country
United States
Facility Name
Indiana Ohio Heart
City
Fort Wayne
State/Province
Indiana
ZIP/Postal Code
46804
Country
United States
Facility Name
University of Maryland Medical Center
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21201
Country
United States
Facility Name
Suburban Hospital
City
Bethesda
State/Province
Maryland
ZIP/Postal Code
20814
Country
United States
Facility Name
MidMichigan Medical Center Midland
City
Midland
State/Province
Michigan
ZIP/Postal Code
49770
Country
United States
Facility Name
Cardiac & Vascular Research Center of Northern Michigan
City
Petoskey
State/Province
Michigan
ZIP/Postal Code
49770
Country
United States
Facility Name
Bryan Heart
City
Lincoln
State/Province
Nebraska
ZIP/Postal Code
68506
Country
United States
Facility Name
Columbia University Medical Center
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States
Facility Name
Duke University
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States
Facility Name
Wake Forest University School of Medicine
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27157
Country
United States
Facility Name
TriHealth
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45220
Country
United States
Facility Name
Cleveland Clinic Fairview
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44111
Country
United States
Facility Name
Ohio State Wexner Medical Center
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43210
Country
United States
Facility Name
Baylor Jack and Jane Hamilton Heart and Vascular center- Soltero Cardiovascular Research Center
City
Dallas
State/Province
Texas
ZIP/Postal Code
75226
Country
United States
Facility Name
University of Texas Southwestern Medical Center
City
Dallas
State/Province
Texas
ZIP/Postal Code
75390
Country
United States
Facility Name
University of Virginia Health System
City
Charlottesville
State/Province
Virginia
ZIP/Postal Code
22903
Country
United States
Facility Name
Faculdade de Medicina da UNESP Campus de Botucatu
City
Botucatu
ZIP/Postal Code
18618-686
Country
Brazil
Facility Name
Instituto de Cardiologia do Rio Grande do Sul / Fundação Universitária de Cardiologia (IC - FUC)
City
Porto Alegre
ZIP/Postal Code
90040-371
Country
Brazil
Facility Name
Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (HCFMRP)
City
Ribeirão Preto
ZIP/Postal Code
14048-900
Country
Brazil
Facility Name
Fundação Faculdade Regional de Medicina de São José do Rio Preto
City
São José Do Rio Preto
ZIP/Postal Code
15090-000
Country
Brazil
Facility Name
Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (InCor - HCFMUSP)
City
São Paulo
ZIP/Postal Code
05403-000
Country
Brazil
Facility Name
St. John Regional Hospital
City
Saint John
State/Province
New Brunswick
ZIP/Postal Code
E2L 4L2
Country
Canada
Facility Name
London Health Sciences Center
City
London
State/Province
Ontario
ZIP/Postal Code
N6A 5A5
Country
Canada
Facility Name
Saint Michael's Hospital
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5B 1W8
Country
Canada
Facility Name
CHUM - Hôtel Dieu
City
Montréal
State/Province
Quebec
ZIP/Postal Code
H2W 1T8
Country
Canada
Facility Name
MUHC - Royal Victoria Hospital
City
Montréal
State/Province
Quebec
ZIP/Postal Code
H4A 3J1
Country
Canada
Facility Name
Institut Universitaire de Cardiologie et de Pneumologie de Québec
City
Québec
ZIP/Postal Code
G1V 4G5
Country
Canada
Facility Name
Israeli-Georgian Medical Research Clinic Helsicore
City
Tbilisi
ZIP/Postal Code
0112
Country
Georgia
Facility Name
New Hospitals LTD
City
Tbilisi
ZIP/Postal Code
0114
Country
Georgia
Facility Name
Bokhua Memorial Cardiovascular Center
City
Tbilisi
ZIP/Postal Code
0159
Country
Georgia
Facility Name
Jerarsi JSC
City
Tbilisi
ZIP/Postal Code
0167
Country
Georgia
Facility Name
Tbilisi Heart Center
City
Tbilisi
ZIP/Postal Code
0186
Country
Georgia
Facility Name
Acad. G. Chapidze Emergency Cardiology Center
City
Tbilisi
ZIP/Postal Code
0519
Country
Georgia

12. IPD Sharing Statement

Learn more about this trial

Study to Prevent Acute Kidney Injury After Cardiac Surgery Involving Cardiopulmonary Bypass

We'll reach out to this number within 24 hrs